science
Colon cancer breakthrough keeps patients cancer-free for nearly 3 years
Key takeaways
- A new clinical trial suggests that giving immunotherapy before surgery may dramatically improve outcomes for certain colorectal cancer patients.
- The trial, led by researchers at UCL and UCLH, found that just nine weeks of treatment with pembrolizumab before surgery led to strong and lasting responses in patients with stage two or three colorectal cancer.
- No Cancer Recurrence After Nearly Three Years
Why this matters: new research or scientific developments with potential real-world impact.
A new clinical trial suggests that giving immunotherapy before surgery may dramatically improve outcomes for certain colorectal cancer patients. In the NEOPRISM-CRC study, patients treated with a short course of immunotherapy instead of chemotherapy after surgery have remained cancer-free for nearly three years.
The trial, led by researchers at UCL and UCLH, found that just nine weeks of treatment with pembrolizumab before surgery led to strong and lasting responses in patients with stage two or three colorectal cancer.
No Cancer Recurrence After Nearly Three Years
Article preview — originally published by Science Daily. Full story at the source.
Read full story on Science Daily →
More top stories
Also covered by
Healthline
How This Active Mom of 2 Is Thriving With ‘Chemo-Resistant’ Colon Cancer
Investing.com
Spain services contract for first time in nearly 3 years, PMI shows
Healthline
How This 16-Year-Old Helped His Family Thrive After Dad’s Colon Cancer Diagnosis
Dawn News
Nearly 20,000 patients ‘missing’ after initiating treatment at HIV centres, NA committee told
Aggregated and edited by the Scoop newsroom. We surface news from Science Daily alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop